These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21896907)

  • 1. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic mismatch of tuberculosis drugs.
    Peloquin CA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1666; author reply 1667. PubMed ID: 22337897
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
    Srivastava S; Pasipanodya JG; Meek C; Leff R; Gumbo T
    J Infect Dis; 2011 Dec; 204(12):1951-9. PubMed ID: 22021624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
    Yunivita V; Gafar F; Santoso P; Chaidir L; Soeroto AY; Meirina TN; Te Brake L; Menzies D; Aarnoutse RE; Ruslami R
    J Antimicrob Chemother; 2024 May; 79(5):977-986. PubMed ID: 38459759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
    Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a membrane hybridization array for detection of Mycobacterium tuberculosis complex and resistance to isoniazid and rifampin in sputum specimens, mycobacterial liquid cultures, and clinical isolates.
    Chen CJ; Yang YC; Huang HH; Chang TC; Lu PL
    Kaohsiung J Med Sci; 2019 Oct; 35(10):615-623. PubMed ID: 31433118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
    Morales Pérez C; Gomez-Pastrana D; Aragón Fernández C; Pérez Escolano E
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):388-390. PubMed ID: 30635203
    [No Abstract]   [Full Text] [Related]  

  • 14. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.
    Smith SE; Kurbatova EV; Cavanaugh JS; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Feb; 16(2):203-5. PubMed ID: 22136739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of multidrug-resistant Mycobacterium tuberculosis isolates in Georgetown, Guyana.
    Menner N; Günther I; Orawa H; Roth A; Rambajan I; Wagner J; Hahn H; Persaud S; Ignatius R
    Trop Med Int Health; 2005 Dec; 10(12):1215-8. PubMed ID: 16359400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
    Pienaar E; Dartois V; Linderman JJ; Kirschner DE
    BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
    Gumbo T
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4048-53. PubMed ID: 24798290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.